Prevalence of drug-resistant epilepsy in low and middle income countries: a systematic review and meta-analysis.

Epilepsy BehavMay 31, 2026 (epub)
Clinical ResearchNeurologyPediatrics

Amir Reza Bahadori, Parisa Javadnia, Ghazal Mohseni et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis estimated the prevalence of drug-resistant epilepsy (DRE) in low- and middle-income countries (LMICs). Analyzing data from twelve studies, the pooled prevalence of DRE was found to be 13.3% (95% CI: 9.6-18.0%). The study highlights significant regional variability, particularly higher rates in African countries and among pediatric patients.

Key findings

  • The pooled prevalence of drug-resistant epilepsy in LMICs is 13.3%.
  • Higher DRE prevalence was noted in African countries and upper-middle-income regions.
  • Pediatric-onset epilepsy showed a higher prevalence of DRE compared to adult-onset epilepsy.
  • Publication year was a significant factor in meta-regression analysis.

Why it matters

Understanding the prevalence of drug-resistant epilepsy in LMICs is crucial for developing targeted interventions and improving healthcare strategies. This knowledge can help address the clinical and socioeconomic burdens associated with DRE in these regions.

Source

PubMed · PMID 42218854

Published in Epilepsy Behav. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.